A retrospective chart review characterized clinicians' use of maintenance intravaginal boric acid for women with recurrent vulvovaginal candidiasis or bacterial vaginosis. Average length of use was 13 months with high patient satisfaction and few adverse events. Prospective studies are needed to evaluate the efficacy of maintenance boric acid for these conditions.
We characterized clinician's use of maintenance boric acid for women with recurrent VVC or BV. Average length of use was 13 months with high patient satisfaction and few adverse events.
From the *Department of Obstetrics and Gynecology
†Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine
‡Institute for Genome Sciences, University of Maryland, Baltimore, MD
Sources of Funding: S.T. is a consultant for Biofire diagnostics, S.T. is supported by K23AI125715.
Off-label use/unapproved drugs or products: boric acid is not FDA labeled for treatment of recurrent vulvovaginal candidiasis or bacterial vaginosis.
Conflicts of Interest: None declared.
Correspondence: Susan Tuddenham, MD, MPH, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center, 5200 Eastern Ave, MFL Center, Tower 378, Baltimore, MD, 21224. E-mail: email@example.com.
Received for publication July 12, 2019, and accepted August 25, 2019.
Online date: October 29, 2019